Source:http://linkedlifedata.com/resource/pubmed/id/21278443
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2011-1-31
|
pubmed:abstractText |
In developed countries, there has been a remarkable improvement in mortality from breast cancer, but almost all of that benefit has occurred in the estrogen receptor (ER)(+) and human epidermal growth factor receptor (HER)-2(+) subsets. Triple-negative breast cancer, defined as tumors that are negative for ER, progesterone receptor, and HER-2, represent a minority of breast cancers. However, because of the poor prognosis in this particular subtype, triple-negative disease accounts for a disproportionate number of metastatic cases and breast cancer deaths. While chemotherapy is effective in triple-negative disease, research continues to better target therapies and predict prognosis. Recent studies have suggested a link between BRCA mutations and triple-negative disease, but the nature of this link remains opaque. Antiangiogenic agents such as bevacizumab have demonstrated efficacy across subtypes. More recently, poly(ADP-ribose) polymerase inhibitors appear to take advantage of the concept of synthetic lethality, or dual pathway inhibition, in attacking triple-negative and BRCA-associated tumors. These and other studies in triple-negative disease will help us to better identify effective treatment options and improve outcomes in these patients. This article addresses the nature of, and therapeutic strategies for, triple-negative breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1549-490X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
16 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
71-8
|
pubmed:meshHeading |
pubmed-meshheading:21278443-Antineoplastic Agents,
pubmed-meshheading:21278443-Breast Neoplasms,
pubmed-meshheading:21278443-Chemotherapy, Adjuvant,
pubmed-meshheading:21278443-Female,
pubmed-meshheading:21278443-Humans,
pubmed-meshheading:21278443-Molecular Targeted Therapy,
pubmed-meshheading:21278443-Receptor, erbB-2,
pubmed-meshheading:21278443-Receptors, Estrogen,
pubmed-meshheading:21278443-Receptors, Progesterone
|
pubmed:year |
2011
|
pubmed:articleTitle |
Directed therapy of subtypes of triple-negative breast cancer.
|
pubmed:affiliation |
University of North Carolina, Chapel Hill, North Carolina 27599-7305, USA. lisa_carey@med.unc.edu
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|